Jordan V C, Phelps E, Lindgren J U
Department of Human Oncology, University of Wisconsin, Madison 53792.
Breast Cancer Res Treat. 1987 Oct;10(1):31-5. doi: 10.1007/BF01806132.
The effects of the antiestrogens tamoxifen and keoxifene on the bone density of intact and ovariectomized female rats were determined after 4 months of therapy. The antiestrogens did not cause a decrease in bone density in intact animals, although uterine wet weight did decrease. Ovariectomy caused an increase in body weight (25%) and a significant decrease in femur density (P less than 0.01). Antiestrogens did not further decrease the bone density of ovariectomized rats but rather helped to maintain bone density. Antiestrogens as well as estrogen (oral estradiol benzoate 25 micrograms daily) helped to maintain bone density in the range observed for the intact rats, but inhibited estrogen stimulation of uterine weight. These contrasting pharmacological actions of antiestrogens suggest that patients receiving long-term adjuvant tamoxifen therapy for breast cancer should be evaluated to determine whether tamoxifen can retard the development of osteoporosis.
在治疗4个月后,测定了抗雌激素药物他莫昔芬和凯昔芬对完整雌性大鼠及去卵巢雌性大鼠骨密度的影响。抗雌激素药物并未导致完整动物的骨密度降低,尽管子宫湿重确实有所下降。去卵巢导致体重增加(25%),股骨密度显著降低(P<0.01)。抗雌激素药物并未进一步降低去卵巢大鼠的骨密度,反而有助于维持骨密度。抗雌激素药物以及雌激素(每日口服25微克苯甲酸雌二醇)有助于将骨密度维持在完整大鼠所观察到的范围内,但抑制了雌激素对子宫重量的刺激作用。抗雌激素药物的这些截然不同的药理作用表明,应对接受乳腺癌长期辅助他莫昔芬治疗的患者进行评估,以确定他莫昔芬是否能够延缓骨质疏松症的发展。